MTX-531-001 Phase 1 Study in Advanced Solid Tumors

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a first-in-human, Phase 1, open-label study evaluating MTX-531, an investigational dual EGFR/PI3K inhibitor, in adults with advanced solid tumors. The study will evaluate the safety and tolerability of MTX-531, determine the maximum tolerated dose and recommended Phase 2 dose, and assess how the drug is processed by the body and its preliminary anti-tumor activity.
Epistemonikos ID: ccd895b53081062559c726dc41332ff0531aba28
First added on: Oct 16, 2026